Special note: The overall market situation of domestic veterinary drug raw materials is relatively weak
The overall performance of penicillin products was relatively weak. In April, the decline in amoxicillin and ampicillin narrowed, while amoxicillin clavulanate potassium, penicillin sodium, and penicillin potassium industrial salt experienced significant declines, with some products falling by more than 5%.
Amoxicillin and amoxicillin sodium. Amoxicillin saw a stable market trend in the fifth week of April; amoxicillin sodium, with a market price ranging from 300 to 340, experienced a weaker market trend in April.
Amoxicillin and clavulanate potassium have a relatively weak performance, with a market price of 485. The month-on-month decrease is 0.9%, and the year-on-year decrease is 34.1%. It is the lowest point in the same period of the past five years, and the market trend in April is downward.
Ampicillin and ampicillin sodium. Ampicillin is operating weakly, with a market price of 185; ampicillin sodium is priced between 280 and 325, and the market trend is downward in April.
Penicillin sodium, operating at a relatively weak level, has a market price of 105-115 per billion, with a month-on-month decrease of 0.5%, a narrowed decrease of 0.3 percentage points, and a year-on-year decrease of 29.2%. It has been hovering at a low level for the past five months.
Penicillin potassium industrial salt is operating at a relatively weak level, hitting a new low in the past six months. The trading price is between 58-68/billion, with a month-on-month decrease of 0.3% and a year-on-year decrease of over 40%. The average prices for the same period in the past five years from 2025 to 2021 were 116, 115, 144, 125, and 96, respectively.
Cefotaxime sodium, cefotaxime hydrochloride, and cefquinome sulfate. Cefotaxime sodium is operating steadily, with a market price of 850, showing little change compared to last week's market situation, and a year-on-year decrease of over 10%. Cefotaxime hydrochloride is operating steadily, with a market price ranging from 750 to 860. The average prices for the same period in the past three years from 2025 to 2023 were 1030, 970, and 1190 respectively. Cefquinome sulfate is operating weakly, with a market price of 3920, showing a month-on-month decrease of 0.4% and a year-on-year decrease of 18.9%. The average prices for the same period in the past five years from 2025 to 2021 were 4860, 5520, 6158, 6900, and 8350 respectively.
The original article of Asia-Pacific Easy and Data Analysis Research Institute is copyrighted. The market data analysis is for the comprehensive price of bulk products and is not used as an investment basis.
The overall performance of tetracycline and chloramphenicol products was relatively weak. In April, florfenicol experienced volatile adjustments, surging to the 170-line mark before falling back, with a decrease of over 3%. Doxycycline hydrochloride decreased by over 5%, and oxytetracycline hydrochloride decreased by over 3%.
Fluoroquinolone, with a relatively weak performance, experiences significant variations in transaction prices across different regions and brands, with market prices below 170. After a three-month market adjustment, as we enter the second quarter in April, the trading market has cooled down and experienced a correction.
Thiamphenicol, with a stable market situation.
Doxycycline hydrochloride, market sentiment has cooled and declined.
Oxytetracycline and oxytetracycline hydrochloride. Oxytetracycline is operating weakly, with a narrowing decline; oxytetracycline hydrochloride has seen active trading in April, with significant price differences across regions and brands, trading within a range of 95-105. The average prices for the same period over the past five years, from 2025 to 2021, are 92, 93, 97, 108, and 114 respectively.
Chlortetracycline hydrochloride, with a stable market situation.
In the first quarter, the chloramphenicol products, florfenicol, saw a stable market trend at low prices from January to March, with average prices of 169, 160, and 164 respectively. There was a slight rebound in market conditions at the end of February and the beginning of March, with prices ranging from 159 to 169 in March. The average price of thiamphenicol in the first quarter was 169.
The overall market for aminoglycoside products has declined.
Neomycin sulfate, with an overall stable market situation, has a market price ranging from 145 to 155 per billion. The market trend remained stable in April.
Spectinomycin dihydrochloride (sulfate) has been operating with a relatively strong performance, but its growth rate has narrowed. The market price ranges from 545 to 565. The average prices from 2025 to April 2023 were 570, 495, and 513 respectively.
Streptomycin sulfate, with a stable market situation.
Amprolium sulfate has a stable market situation, with little change compared to last week.
Kanamycin monosulfate, with a market transaction price of around 290/billion, saw a month-on-month decrease of 1.7%, while its year-on-year transaction price remained unchanged. The market trend in April was generally strong.
Amikacin sulfate, with a market price of 730, has shown a stable trend in April.
Gentamicin sulfate, with a stable market situation.
In the first quarter, the overall trend of aminoglycoside products was mainly stable. Neomycin sulfate exhibited a trend of "steady start - narrow range stability - slight decline". From January to February, the price mainly fluctuated within a narrow range of 153-155/billion, and in March, the price range shifted downwards to 145-155/billion, with the year-on-year decrease expanding from 3% to 6%. The market as a whole was in the phase of destocking, with downward pressure persisting, but the fluctuation range within the quarter was not significant. In mid-to-late March, interest increased and trading became active; the transaction price range for spectinomycin dihydrochloride was 535-555, with an increase of over 3%; streptomycin sulfate was 265-310; the average prices for apramycin sulfate and kanamycin monosulfate were 191 and 294, respectively.
The overall market for macrolides remains stable.
Tylosin tartrate has a stable market situation, with a market price of around 270. In the second quarter of last year, from April to June, the average prices were 272, 287, and 280 respectively. In the third and fourth quarters, the average prices were 285 and 292 respectively.
Tilmicosin and tilmicosin phosphate. The market price of tilmicosin is around 360; the market price of tilmicosin phosphate is around 300, which is basically the same as last week's price, with a year-on-year decrease of 6.5%. The average prices for the second quarter of last year, from April to June, were 306, 336, and 425 respectively.
Tartaric acid kitasamycin, with a stable market situation.
Tylvalosin tartrate, with a trading market price of 370-390, has shown a steady decline in the past four weeks, with a year-on-year decrease of 3.9%.
Tylosin, with a market price of 5950, has seen a stable trend in April.
Erythromycin thiocyanate is mainly characterized by a stable market situation, with a market price of around 480. The market trend in April is expected to remain stable.
Colistin sulfate is highly sought after and actively traded, with a market price of around 115. The average market prices for the past three years, from 2025 to 2023, were 112, 110, and 97 respectively.
Tylosin fumarate has a stable market situation.
Lincomycin hydrochloride, with a market price of 310-330/billion, is basically unchanged from the transaction price of last week, with a year-on-year decrease of 19.2%.
In the first quarter, macrolide products underwent a middle note adjustment, maintaining overall stability and exhibiting a trend of steady increase followed by a decline. Tylosin tartrate and tylvalosin tartrate started off smoothly in January, with average prices of 280 and 398 respectively. In February, they saw a slight decrease, with average prices of 275 and 390 respectively. In early March, influenced by the situation in the Middle East, the market experienced a rapid increase. Tilmicosin began to gain momentum in the second week of March, with the market's highest price rising above 350. By the end of March, there was a gradual correction, with average prices for January to March being 364, 350, and 345 respectively. For erythromycin thiocyanate, the average price in the first quarter was 481, and the transaction average price was lower than that of the same period last year.
The lincomycin hydrochloride, a lincomycin antibiotic, mainly experienced a downward trend in the first quarter, with a decrease of 3.2%. The average prices from January to March were 331, 321, and 329 respectively. The average prices in the first quarter of 2025 were 443, 439, and 420 respectively. The average prices in the first quarter of 2024 were 298, 305, and 299 respectively. The market situation in the first quarter of 2026 is close to that of 2024.
Original article from Asia-Pacific Easy Data Analysis Research Institute. Reproduction is prohibited without permission. All rights reserved. For reproduction and quotation, please contact the author and indicate the original source.
Quinolones are experiencing a period of adjustment amidst market fluctuations.
Enrofloxacin and enrofloxacin hydrochloride. The market price is around 170, with an upward trend in April.
Ciprofloxacin lactate (hydrochloride) has a price of 165. The overall market situation is stable, which is more stable compared to last week. The year-on-year decrease is 11.3%. The average prices from 2025 to April 2023 are 186, 196, and 234 respectively.
Sarafloxacin hydrochloride, with a stable market situation.
Mapofloxacin, with a market price of 2200, has seen a month-on-month decrease of 1.3% and a year-on-year decrease of 17.4%.
The market for sulfa products is mainly stable.
Sulfamethoxazole (sodium) has a stable market situation, with transaction prices ranging from 199 to 230, which is basically the same as that of the same period last year.
Sulfamethoxazole (sodium) has a stable market situation, with a market price ranging from 230 to 245.
Sulfamethoxazole (sodium), market price 100-145.
Sulfadiazine (sodium) has a stable market situation, with a market price of 155. The average prices for the same period in 2025-2023 were 165, 161, and 201 respectively.
Sulfamethazine (sodium) has a market price of 100-110, which is stable compared to last week's market conditions, with a year-on-year increase of 22.2%.
Sulfamethoxazole sodium is basically unchanged in price compared to last week.
Sulfamethoxazole and pyrimethamine sodium, with prices basically unchanged from last week, had average prices of 215, 228, and 300 from 2025 to April 2023, respectively.
Sulfachloropyridazine sodium's price remained basically unchanged compared to the previous week, with average prices of 171, 140, and 180 from 2025 to April 2023.
Dimethoxypyridine, with stable market demand.
Trimethoprim, trimethoprim lactate. Trimethoprim, market price 245; trimethoprim lactate, market price 190, with a downward trend in April.
The anti-parasitic products have been operating steadily overall. Albendazole, avermectin, and cyromazine have been in high demand, while metronidazole, dimetridazole, and levamisole hydrochloride have seen a decline in market demand.
Abendazole is highly sought after, with active trading. Its market price ranges from 145 to 165, marking a month-on-month increase of 1.8%. Compared to the same period last year, the price remains stable. Transaction prices vary significantly depending on the region and brand. In the first quarter, the price started low but rose steadily. It hit its lowest point at the end of January and remained low until February. By mid-March, it began to surge, entering a rapid growth phase. In the second quarter, the market trend showed a steady but upward trajectory.
Fenbendazole has remained stable compared to last week's market situation.
Avermectin, with active trading, continues to rise in market price, trading at around 640. The market trend is upward in April.
Ivermectin, with relatively strong performance, has a market price of 800. The average prices for the same period in the past five years from 2025 to 2021 were 789, 846, 1092, 1460, and 1410 respectively.
Diclazuril, with a market price of 1060, has seen an increase compared to last week's market situation, with a year-on-year increase of 3.9%.
Tuoqu Zhuli, with strong operational capabilities, has a market price of 860.
Levamisole hydrochloride, market fluctuates and adjusts.
Amprolium hydrochloride has a stable market situation, with a market transaction price of 320. The transaction price range in April was 329-315.
Metronidazole, with a stable market situation, has a market price of around 80, which is basically the same as the price of last week. The average prices for the same period in 2025, 2022, and 2023 were 79, 78, and 85 respectively. The market trend in April is upward.
Demenidazole, with a market price of around 100, is basically unchanged compared to last week's price. The average prices for the same period from 2025 to 2023 were 89, 99, and 147 respectively.
Praziquantel, with a slight decrease compared to last week's market situation.
Cyromazine, with high demand and active trading, has a market price of 115, and the market trend is upward in April.
In the first quarter, anti-parasitic products underwent a volatile adjustment, showing a trend of initial increase followed by a decline. The average prices of albendazole for January to March were 134, 135, and 155 respectively, with an increase of over 5% in early March. For metronidazole and dimetridazole, the market remained stable in January and February, but saw a surge in prices at the end of February and early March. The market price range for metronidazole in March was 76-85, and for dimetridazole was 105-115. By the end of March, the market experienced a downward correction.
All rights reserved by Asia-Pacific Easy Harmony and Data Analysis Research Institute for the original article. The market data analysis pertains to the comprehensive price of bulk products.
The overall trend of antipyretic and analgesic products remains stable.
Flunixin meglumine, with a market price range of 360-380, has seen a month-on-month decrease of 1.5% and a year-on-year decrease of over 10%. The market trend in April is downward.
Analgin, with a stable market situation.
Acetaminophen, with fluctuating market conditions.
Aminopyrine, with a market price of 105, has seen an increase compared to last week's market conditions, while remaining basically unchanged compared to the same period last year. The market conditions in the first quarter stabilized around 100.
Aminophylline, with a stable market situation, has a market price of 110.
Aspirin, with a market price of 21900/ton.
Taurine: market sentiment cools down and prices adjust downwards.
After a strong market surge in March, the price of Carbasalate Calcium has seen a partial brand-specific correction to below 30 in April.
Acetyl mequindox, market fluctuates and adjusts.
Sodium camphor sulfonate, with a stable market situation.
Chlorpheniramine, with a downward trend, saw a volatile rise in early March in the first quarter, followed by a market downturn in April.
Sodium salicylate, operating at a relatively strong level, is traded at a price of 26,500/ton.
Citric acid, with its supply alleviated, continues to rise in market price, currently at 4600/ton.
Sodium citrate, with a rising market trend, has a market price of 4690/ton.
Sodium carbonate, market price 1960/ton.
Sodium bicarbonate, with a market price of 2100/ton.
Glucose, trading at a price range of 3850-6400/ton, is performing relatively strong.
Jiayi powder, with a trading price of 2680-3260/ton, is operating relatively strongly.
Soluble starch, operating at a relatively strong level, has a market price of 12,700/ton.
Beta-cyclodextrin, with strong performance, has a market price of 18,500/ton.
To learn more information, please join the membership of Asia-Pacific Easy and Data Analysis Research Institute to grasp the market changes in real time.
The overall trend of plant-based traditional Chinese medicinal materials remains stable.
Shuanghuanglian extract, 40-80.
Astragalus Polysaccharide Extract, 50-100.
Scutellaria baicalensis extract, 110-150.
Licorice extract, 60-100.
Honeysuckle extract, 60-100.
Honeysuckle, 55-120.
Huanglian, 240-290.
Astragalus, 10-15.
Scutellaria, 16-25.
Yanhusuo, 55-65.
Chenpi, 10-13.
Hawthorn, 4-6.
Licorice, 10-14.
Dried ginger, 16-25.
Safflower, 50-79.
Banlangen, 12-22.
The overall market for vitamin products has declined, with some products experiencing a decrease of over 3%.
VA, mixing material 105, water solubility 120, market has declined.
VB1, market stable, nitric acid 235, hydrochloric acid 280.
VB2, 98% purity priced at 278, 80% purity priced at 76.
VB6, with stable market conditions, has a market price of 110.
VB12 1%, market price 98, stable market.
VC, market quotation: feed grade 19-23, pharmaceutical grade 30, with stable market conditions.
VD3, market price for mixing is 140, water solubility is 160, and the market trend is slowing down.
VE, mixing material 100-110, water solubility 120, stable with a slight decrease.
VK3, with a market price of 90, has seen a steady decline.
Calcium pantothenate, market price 71, market trend declining.
Niacinamide, with a market price of 50, has a stable market situation.
Biotin 2%, market price 38.
Folic acid, with a market price of 339, has a stable market situation.
The above is the market data of veterinary drug ingredients released by Asia-Pacific Easy and Data Analysis Research Institute. Please leave a message for correction. To learn more information, please join as a member to grasp the dynamic changes of the market in real time.
